The tryptophan metabolites indole, indole 3-acetate and tryptamine were identified in mouse cecal extracts and fecal pellets by mass spectrometry. The aryl hydrocarbon receptor (AHR) agonist and antagonist activities of these microbiota-derived compounds were investigated in CaCo-2 intestinal cells as a model for understanding their interactions with colonic tissue which is highly aryl hydrocarbon (AH)-responsive. Activation of AH-responsive genes demonstrated that tryptamine and indole 3-acetate were AHR agonists, whereas indole was an AHR antagonist that inhibited 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 expression. In contrast, the tryptophan metabolites exhibited minimal anti-inflammatory activities, whereas TCDD decreased phorbol ester-induced CXCR4 gene expression, and this response was AHR-dependent. These results demonstrate that the tryptophan metabolites indole, tryptamine and indole 3-acetate modulate AHR-mediated responses in CaCo-2 cells, and concentrations of indole that exhibit AHR antagonist activity (100-250 μM) are detected in the intestinal microbiome.
INTRODUCTION
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that forms a nuclear heterodimer with the AHR nuclear translocator protein to activate gene transcription (Denison et al., 2011; Hankinson, 1995) . AHR complex-mediated gene expression involves interaction with dioxin responsive elements (DREs) in 5'-promoter regions of target genes, and the overall mechanisms of this response have been intensively investigated using the CYP1A1 gene and other drug-metabolizing enzymes as models (Whitlock, 1999) . More recent studies demonstrate that this genomic pathway for activation of the AHR is more complex than the classical induction of CYP1A1, and there is also evidence for extranuclear activity of the AHR (Huang and Elferink, 2012; Tanos et al., 2012) . 2,3,7,8-Tetrachlordibenzo-p-dioxin (TCDD) and structurally related halogenated aromatics and polynuclear aromatic hydrocarbons were among the first compounds identified as AHR ligands (Bigelow and Nebert, 1982; Poland et al., 1976) .
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CYP1A1 by TCDD and is an AHR antagonist (Jin et al., 2012) and this is typical of a tissuespecific selective AHR modulator (SAhRM).
There is increasing evidence that the endogenous AHR plays an important functional role in multiple tissues and organs (Barouki et al., 2007; McMillan and Bradfield, 2007) and this has been amply demonstrated in AHR -/-mice and by AHR silencing in non-transformed and transformed cell lines. For example, in gastrointestinal tissues including lymphoid tissues, the receptor and its ligands modulate inflammatory responses including those associated with induced colitis in animal models (Arsenescu et al., 2011; Benson and Shepherd, 2011; Furumatsu et al., 2011; Kawajiri et al., 2009; Kiss et al., 2011; Li et al., 2011; Singh et al., 2011) . The AHR agonist β-naphthoflavone significantly suppresses dextran sodium sulfate-induced colitis in C57BL/6 mice (Furumatsu et al., 2011) and in the APC min model of colon cancer, the loss of the AHR enhances colon carcinogenesis and AHR ligands inhibit polyp formation in APC min /AHR +/+ mice (Kawajiri et al., 2009 ).
Previous studies in our laboratory have identified the tryptophan metabolite indole as a major extracellular metabolite produced by gut bacteria such as Escherichia coli (Bansal et al., 6 MOL #91165 et al., 2007) , and the AHR plays an important role in maintaining gut homeostasis (Arsenescu et al., 2011; Benson and Shepherd, 2011; Furumatsu et al., 2011; Kawajiri et al., 2009; Kiss et al., 2011; Li et al., 2011; Singh et al., 2011) . Therefore, the major objectives of this research were to investigate the AHR agonist or antagonist activity of tryptophan-derived microbiota metabolites in CaCo-2 human epithelial colon colon cancer cells and other cell lines, and determine their role in modulating inflammation in CaCo-2 cells. The results clearly demonstrate the production of high levels of tryptophan metabolites in the gut microbiome, and the AHR agonist and antagonist activities of these metabolites are both response-, cell context-and compound-dependent which is typical of a SAhRM.
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methanol/chloroform extraction method (Sellick et al., 2010) with minor modifications. Cold methanol/chloroform (2:1, v/v; 1.5 mL) was added to a pre-weighed cecal or fecal sample and homogenized on ice. The sample tube was centrifuged at 15,000 x g for 10 min at 4°C and the supernatant transferred to a new sample tube through a 70 μm cell strainer. Ice-cold water (0.6 mL) was added and the sample tube was vortexed and centrifuged (15,000 x g, 5 min, 4°C) to obtain phase separation. The upper and lower phases were separately collected in fresh sample tubes with a syringe, taking care not to disturb the interface. The polar (upper) phase (500 μL)
was evaporated to dryness in a Savant speedvac concentrator (Thermo Scientific, Asheville, NC), and then reconstituted in 50 μL of methanol/water (1:1, v/v). Extracted metabolites were stored at -80 o C until analysis.
Metabolite analysis.
Prior to sample analysis, MS parameters were optimized for each target metabolite to identify the MRM transition (precursor/product fragment ion pair) with the highest intensity under direction injection at 10 μL/min. The following parameters were optimized operating in positive mode: declustering potential (DP), entrance potential (EP), collision energy (CE), and collision cell exit potential (CXP). The optimized parameter values for the target metabolites analyzed in this study are shown in Supplemental Table 1 . The target metabolites in samples were detected and quantified on a triple quadrupole linear ion trap mass spectrometer (3200 QTRAP, AB SCIEX, Foster City, CA) coupled to a binary pump HPLC (1200 Series, Agilent, Santa Clara, CA). Peak identification and integration were performed using Analyst software (version 5, Agilent, Foster City, CA). Samples were maintained at 4°C
on an autosampler prior to injection. Chromatographic separation was achieved on a hydrophilic interaction column (Luna 5 μm NH 2 100 Å 250 mm × 2 mm, Phenomenex, Torrance, CA) using a solvent gradient method (Bajad et al., 2006) . Solvent A was an ammonium acetate (20 mM)
This article has not been copyedited and formatted. The final version may differ from this version. nuclei were collected. Nuclei were then sonicated to desired chromatin length (~200-1500 bp).
The sonicated chromatin was immunoprecipitated with normal rabbit IgG or AHR antibodies and protein A-conjugated magnetic beads at 4°C for overnight. After the magnetic beads were extensively washed, protein-DNA crosslinks were reversed and eluted. DNA was prepared by proteinase K digestion followed by PCR amplification. The CYP1A1 primers were 5'-TCA GGG CTG GGG TCG CAG CGC TTC T-3' (sense), and 5'-GCT ACA GCC TAC CAG GAC TCG GCA G-3' (antisense), and then we amplified a 122-bp region of human Cyp1A1 promoter which contained the AHR binding sequences. PCR products were resolved on a 2% agarose gel in the presence of ETBR.
Quantitative real-time PCR. cDNA was prepared from the total RNA of cells using amfiRivert cDNA Master Mix Platinum (GenDEPOT, Barker, TX). Each PCR was carried out in triplicate in a 20 μL volume using SYBR Green Mastermix (Applied Biosystems) for 15 min at 95°C for initial denaturing, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min in the Western blot analysis. Cells (3 x 10 5 ) were plated in six-well plates in DMEM media containing 2.5% FBS (and 1X MEM non-essential amino acid for CaCo-2 cells) for 16 hr and then treated with different concentrations of the compounds. Cellular lysates were prepared in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 2 mM ethylenediaminetetraacetic acid, 150 mM NaCl, 0.5% deoxycholate, 0.1% sodium dodecylsulfate (SDS), 1 mM NaF, 1 mM Na 3 VO 4 ,
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detection of specific proteins was carried out by enhanced chemiluminescence. Loading differences were normalized using a polyclonal β-actin antibody. 
Transfection
RESULTS
Previous studies show that indole is a major bacterial metabolite and, in this study, we analyzed the cecal material (luminal contents and tissue) and fecal pellets from 6-week old C57BL/6 mice for the presence of indole and other tryptophan-derived microbiota metabolites.
The major tryptophan metabolites identified include indole, indole 3-acetate and tryptamine (Fig.   1A ). Levels of these metabolites were quantified in both cecal extracts and fecal pellets using MRM mass spectrometry, and the concentration of indole in the cecal material ranged between 200 -400 μM while tryptamine and indole 3-acetate were less abundant (concentrations ranging from 10 -20 and 10 -40 μM, respectively). Similar levels of these metabolites were detected in fecal pellets (Fig. 1D ).
These compounds were investigated as AHR agonists and antagonists in CaCo-2 colon cancer cells. The effects of the tryptophan metabolites alone and in combination with 10 nM TCDD on CYP1A1 mRNA and CYP1A1, CYP1B1 and AHR protein levels (markers of altered AH-responsive gene expression) were determined. Treatment of CaCo-2 cells with tryptamine (50 -1000 μM) induced CYP1A1 mRNA and protein and CYP1B1 protein ( Fig. 2A ) with significant induction at the lowest concentration (50 μM); AHR levels were unchanged at 50 -500 μM concentrations but decreased at the highest concentration (1000 μM) (Fig. 1A) . High concentrations of tryptamine also decreased expression of CYP1A1/CYP1B1 proteins and this may be due to cytotoxicity (Supplemental Fig. 1 ). TCDD alone decreased AHR protein levels as previously described for other AHR agonists in colon cancer cells (Kawajiri et al., 2009) . TCDD also induced CYP1A1 (mRNA and protein) and CYP1B1. In combination with tryptamine, the TCDD-induced responses were slightly attenuated at the two highest concentrations of tryptamine (500 and 1000 μM), indicating that this compound is primarily an AHR agonist in This article has not been copyedited and formatted. The final version may differ from this version. 
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CaCo-2 cells as previously described in other cancer cell lines (Heath-Pagliuso et al., 1998; Miller, 1997; Vikstrom Bergander et al., 2012) , with possible partial antagonist activity at the higher concentrations. In contrast to a previous report (Vikstrom Bergander et al., 2012) , our data show that the AHR agonist activity of tryptamine (i.e. CYP1A1 induction) was not affected by a monoamine oxidase inhibitor (Supplemental Fig. 2 ).
Indole 3-acetate was also identified in the cecal extract and feces ( Fig. 1 ) and the activity of this compound was compared to that of the uremic toxicant 3-indoxyl sulfate which has previously been described as an AHR agonist in liver cancer cell lines .
Both indole 3-acetate and 3-indoxyl sulfate induced CYP1A1 (mRNA and protein) and CYP1B1
(protein) and, in combination with TCDD, indole 3-acetate did not affect CYP induction by TCDD (Figs. 2B and 2C). Although 3-indoxyl sulfate was an AHR agonist, induction of CYP1A1 and CYP1B1 protein by TCDD was decreased in CaCo-2 cell cotreated with TCDD plus 3-indoxyl sulfate, suggesting some partial AHR antagonist activity. However, we also observed that 50 μM 3-indoxyl sulfate was cytotoxic (Supplemental Fig. 1 ), and this may contribute to decreased CYP1A1/CYP1B1 proteins. The two 3-substituted indole derivatives differed with respect to their effects on the AHR; like TCDD, 3-indoxyl sulfate decrease AHR expression, whereas indole 3-acetate did not affect levels of AHR protein, even though the fold induction of CYP1A1 mRNA by this compound was similar to that observed for TCDD.
Treatment of CaCo-2 cells with 50 -1000 μM indole significantly induced CYP1A1 mRNA levels only at the two higher concentrations (500 -1000 μM); however, this was not accompanied by induction of CYP1A1 and CYP1B1 proteins and levels of the AHR protein were unchanged (Fig. 2D) . In combination experiments, indole (500 -1000 μM) inhibited TCDD-mediated induction of CYP1A1 (mRNA and protein) and CYP1B1 protein, and
downregulation of the AHR demonstrated that indole was an AHR antagonist for these responses (Fig. 2D) . The EC 50 values for induction of CYP1A1 mRNA by tryptamine indole 3-acetate and indole were 0.048, 0.37 and > 1 mM, respectively.
We further investigated the AHR antagonist activities of indole as an inhibitor of TCDDinduced CYP1A1 gene transcription after treatment of CaCo-2 cells for 2 hr (Fig. 3A) . The results showed that at this early time point, indole was a full AHR antagonist, whereas tryptamine and indole 3-acetate did not inhibit TCDD-induced CYP1A1 RNA (Fig. 3B) . Indole also significantly inhibited TCDD-induced Cyp1a1 and Cyp1b1 mRNA expression in mousederived colonic crypts in 3-dimensional culture ( Fig. 3C ) and these data complemented results in
CaCo-2 cells. We also observed that indole inhibited indole 3-acetate-induced CYP1A1 mRNA (2 and 24 hr) and protein (24 hr) expression in CaCo2 cells (Fig. 3D) , demonstrating potential inhibitory interactions among the indole-derived AHR agonsits. Effects of the tryptophan metabolites on TCDD-induced recruitment of the AHR complex to a DRE region on the CYP1A1 promoter were investigated in ChIP assays (Fig. 3E) . Confirmation of the AHR agonist/antagonist activity of the tryptophan metabolites was determined in MDA-MB-468 and MDA-MB-231 cells which we have previously used to investigate the activities of several AHR-active pharmaceuticals (Jin et al., 2012) . Figure 4A This article has not been copyedited and formatted. The final version may differ from this version. (Furumatsu et al., 2011; Kawajiri et al., 2009; Villard et al., 2007) and CXCR4 is suppressed by AHR ligands in breast cancer cells (Hsu et al., 2007) . Treatment of CaCo-2 cells with tryptamine or indole slightly increased ICAM-1 mRNA; indole 3-acetate and TCDD decreased ( Fig. 5A ) and indoxyl 3-sulfate had no effect on expression of this gene (Supplemental Fig. 3 ). Phorbol-12-myristate 13-acetate (PMA) only slightly induced ICAM1 in CaCo-2 cells and, in combination with the tryptophan metabolites, expression was increased (tryptamine, indole), decreased (indole-3-acetate) or unchanged (3-indoxyl sulfate), and similar results were observed for TCDD. Expression of MMP-9 in CaCo-2 cells was low and unaffected by the indole derivatives or TCDD (Fig. 5B) ; MMP-9 was induced 10-fold by PMA and, in the cotreatment experiment, only tryptamine (slight decrease) affected the PMA-induced response.
IL-β expression was slightly increased (indole and indole 3-acetate), decreased (TCDD) or unaffected (indole and 3-indoxyl sulfate) by the AHR ligands and PMA only slightly induced (1.5 -2.5-fold) IL-1β mRNA levels (Fig. 5C ). Cotreatment with PMA plus the indole derivatives resulted in dose-dependent effects for some compounds; 100 and 500 μM tryptamine enhanced and inhibited IL-1β mRNA levels, respectively; indole and indole 3-acetate enhanced and 3-indoxyl sulfate decreased IL-1β mRNA and TCDD slightly decreased the PMA-induced response. Tryptamine, indole-3-acetate, TCDD and 3-indoxyl sulfate decreased and indole had no effect on endogenous CXCR4 gene expression. PMA significantly induced CXCR4 mRNA levels and cotreatment with the highest concentration of all four tryptophan metabolites and TCDD decreased PMA-induced CXCR4 mRNA levels (note: 100 μM indole increased this response). The most consistent effect of TCDD and the tryptophan metabolites was the decreased expression of CXCR4 and this response has previously been observed for other AHR agonists in breast cancer cells (Hsu et al., 2007) . Figure 6A show that the AHR antagonist CH223191 alone did not affect basal or PMA-induced CXCR4 mRNA levels but significantly blocked the effects (downregulation) of TCDD, and CH223191 also inhibited TCDD (± PMA)-induced CYP1A1 mRNA levels in CaCo-2 cells. CH223191 partially reversed tryptamine-mediated downregulation of (induced) CXCR4 but did not significantly alter the effects of indole 3-acetate or 3-indoxyl sulfate (Fig. 6B) . It was also evident that CH223191 was less effective as an inhibitor of tryptamine-/indole 3-acetate-/3-indoxyl sulfate-induced CYP1A1 mRNA (Fig. 6C ) than observed for TCDD (Fig. 6A ) and these results are consistent with the reported activity of CH223191 as specific inhibitor of TCDD and related halogenated aryl hydrocarbons (Zhao et al., 2010) . However, AHR knockdown by RNA interference shows CYP1A1 inducibility is decreased for both TCDD and the tryptophan This article has not been copyedited and formatted. The final version may differ from this version. 
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metabolites (Fig. 6D) . It should also be noted that CH223191 inhibits induction of Ahresponsive luciferase activity by the natural ligand 6-formylindo [3,2b] carbazole and methyl 2-(1-H'-indolo-3'-carbonyl)-thiazole-4-carboxylate in HepG2 liver cells suggesting a broader spectrum of AHR antagonist activity for this compound (Choi et al., 2012) .
A previous study reported that several AHR agonists decreased β-catenin expression in DLD-1, SW480 and HCT116 colon cancer cells (Kawajiri et al., 2009) ; however, TCDD did not affect β-catenin levels in CaCo-2 cells and, among the tryptophan metabolites, only the higher concentrations of tryptamine decreased β-catenin protein levels (Supplemental Fig. 4A ) and this may be due to cytotoxicity (Supplemental Fig. 1 ). However, the AHR antagonist CH223191 did not modulate downregulation of β-catenin by tryptamine but clearly inhibited induction of CYP1A1 protein by tryptamine (500 μM) (Supplemental Fig. 4B ). The effects of 100 μM tryptamine on CYP1A1 downregulation were not affected by CH223191. These results demonstrate that the AHR-dependent effects of TCDD and the indole derivatives are responseand cell context-dependent which is consistent with their activity as SAhRMs.
DISCUSSION
The AHR and its ligands play an increasingly important role in gut homeostasis and in various intestinal diseases including colitis and colon cancer (Arsenescu et al., 2011; Benson and Shepherd, 2011; Furumatsu et al., 2011; Kawajiri et al., 2009; Kiss et al., 2011; Li et al., 2011; Singh et al., 2011) . For example, the AHR is required for the postnatal expansion of CD4-RORγT + innate lymphoid cells and dietary AHR ligands such as indole-3-carbinol (I3C) promote the postnatal expansion of these cells which protect against intestinal infections (Bansal et al., 2010) . β-Naphthoflavone, a relatively non-toxic AHR agonist, protects against dextran sodium sulfate-induced colitis in a mouse model and decreased lipopolysaccharide-induced inflammatory responses in SW480 colon cancer cells (Furumatsu et al., 2011) . APC min/+ mice are extensively used as a model for intestinal carcinogenesis, and loss of the AHR enhanced cecal tumor incidence and, in wild type mice, dietary administration of I3C or diindolylmethane (AHR agonists) protected against intestinal carcinogenesis (Kawajiri et al., 2009) . These results clearly demonstrate an important role for the AHR and AHR agonists in maintaining gut health and protecting against intestinal diseases.
Tryptophan metabolites such as the indole derivatives have previously been investigated as AHR ligands, and a recent study showed that the AHR agonist kynurenine (Davarinos and Pollenz, 1999) plays an important pro-oncogenic role in glioma (Opitz et al., 2011) . Therefore, the expression of tryptophan metabolites by gut microflora and their AHR agonist or antagonist activities could significantly impact Ah-responsive intestinal functions. Previous studies in our laboratory have identified indole as a major microbial metabolite (Bansal et al., 2010) and indole concentrations in human feces can be in the low mM range (Karlin et al., 1985; Zuccato et al., 1993) . In this study, we used LC-MRM-MS and identified the tryptophan metabolites indole, This article has not been copyedited and formatted. The final version may differ from this version.
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tryptamine and indole-3-acetate in the cecum and feces of 6-week old C57BL/6 mice, at concentrations comparable to those reported in human feces (Karlin et al., 1985; Zuccato et al., 1993) . The concentration of indole was almost an order of magnitude greater than tryptamine or indole-3-acetate in both cecal extracts and fecal samples and concentrations of tryptamine and indole in the cecum and fecal pellets were comparable to those needed for AHR agonist and antagonist activity, respectively. Concentrations of these tryptophan metabolites (Fig. 1 ) are probably underestimated due to the overall efficiencies of extraction which are < 100%.
We used the CaCo-2 intestinal colon cell line as a model to investigate the AHR agonist and antagonist activities of indole, indole 3-acetate and tryptamine, and their effects on CYP1A1 mRNA and protein and CYP1B1 protein expression were determined as a measure of their AHresponsiveness. Moreover, in CaCo-2 cells, we also examined the effects of 3-indoxyl sulfate which has previously been characterized as an AHR agonist . TCDD served as a prototypical agonist, and we also compared the effects of TCDD vs. the tryptophan metabolites on proteasome-dependent downregulation of the AHR protein which is observed for some (e.g. TCDD) but not all AHR ligands (14, 17, 39) . All the tryptophan metabolites exhibit full or partial (indole) AHR agonist activity in CaCo-2 cells and induced CYP1A1 mRNA and protein, whereas induction of CYP1B1 was highly variable. However, after treatment of CaCo-2 cells with tryptamine for 24 hr, there was some indication that this compound may be a partial AHR antagonist (i.e. inhibition of TCDD-induced CYP1A1 and AHR downregulation) and in short term experiments, neither tryptamine or indole 3-acetate inhibited TCDD-induced CYP1A1 gene expression (Fig. 3B) . In contrast, indole exhibited AHR antagonist activity at both the 24 and 2 hr treatment times in CaCo-2 cells using TCDD (Figs. 2D and 3A) and indole 3-acetate (Fig. 3D) as agonists, confirming the AHR antagonist activity of indole and indicating potential This article has not been copyedited and formatted. The final version may differ from this version. (Li et al., 2011) , and we are currently further investigating their interactive effects with microbiota tryptophan metabolites.
Previous reports suggest that AHR agonists modulate inflammatory response genes in colon epithelial and in colon cancer cells (Furumatsu et al., 2011; Kawajiri et al., 2009; Villard et al., 2007) and this included AHR-dependent-inhibition of IL-1β in SW480 cells by β-naphthoflavone (Furumatsu et al., 2011) . In contrast IL-1β and MMP-9 were induced by 3-methylcholanthrene in CaCo-2 cells (Villard et al., 2007) ; however, the role of the AHR in mediating these responses was not confirmed. Results for the tryptophan metabolites in CaCo-2 cells showed highly variable effects of these compounds on endogenous and PMA-induced stress response genes (Fig. 5) . Moreover, TCDD did not affect endogenous or PMA-induced ICAM1, MMP-9 or IL-1β gene expression and the only significant response observed was inhibition of CXCR4 ( Fig. 6A) , and TCDD-induced downregulation of CXCR4 was blocked by the AHR antagonist CH223191. Interestingly, tryptamine, indole 3-acetate and 3-indoxyl sulfate also decreased endogenous and PMA-induced CXCR4 mRNA levels and exhibited the expected TCDD-like AHR agonist activity; however, cotreatment with the AHR antagonist did not reverse CXCR4 downregulation (Figs. 6B and 6C) , suggesting that the effects of these compounds were AHR-independent. An AHR-dependent response previously observed in SW480, DLD-1 and This article has not been copyedited and formatted. The final version may differ from this version.
HCT116 colon cancer cells was the downregulation of β -catenin by several AHR agonists (not TCDD) (Kawajiri et al., 2009) , whereas in CaCo-2 cells, TCDD, indole, indole 3-acetate and 3-indoxyl sulphate did not affect β -catenin levels and the tryptamine response was AHRindependent (Supplemental Fig. 4) . Tissue-and response-specific agonist or antagonist activity of receptor ligands is due to several factors including different ligand-induced conformational changes in the receptor and differential expression of cofactor in various tissues/cells. We previously observed the SAhRM-like activity for a series of AHR-active pharmaceuticals in breast cancer cells (Jin et al., 2012) .
In summary, results of this study demonstrate that the mouse microbiome produces relatively high concentrations of tryptophan metabolites tryptamine, indole 3-acetate and indole, and these compounds differentially activate markers of AH-responsiveness including induction of CYP1A1 and CYP1B1. Previous studies demonstrate that the AHR plays a critical role in intestinal homeostasis and disease, and dietary AHR agonists such as I3C and DIM can protect against induced colitis and colon cancer in mouse models (Arsenescu et al., 2011; Benson and Shepherd, 2011; Furumatsu et al., 2011; Kawajiri et al., 2009; Kiss et al., 2011; Li et al., 2011; Singh et al., 2011 ). Our results demonstrate that microbiota-generated tryptophan metabolites exhibit both AHR agonist and antagonist activities, and these may also be response-and cell context-specific as observed for other SAhRMS (Jin et al., 2012) . Thus, the AHR-active tryptophan metabolites along with other dietary and potential exogenous (i.e. contaminants) AHR ligands can potentially influence host intestinal responses and changes, and levels and ratios of microbiota-derived tryptophan metabolites could affect overall AHR ligand-induced impacts on intestinal functions.
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